This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1.
Worth separating two things that post #58 runs together.
The lyophilised cake is worth looking at before adding diluent. A collapsed or shrunken cake is not a purity finding but it does say something about how the vial was made and how it travelled.
This is the sort of thing that ought to be settled and apparently is not.
Summarising the TB-500 and thymosin beta-4 thread so far, since it is long and the answer is buried: the first reply has the method, the fourth has the correction to it, and the rest is people agreeing at length.
The most useful reply I ever got about TB-500 and thymosin beta-4 was a request to state my units. It sounds like pedantry and it has saved me twice.
Reported local reactions are common enough in first-hand accounts here to be worth mentioning and are not characterised in any published series.
On post #61 — agreed on the reasoning, with one qualification.
Counterpoint on TB-500 and thymosin beta-4, offered without confidence: the same observation is consistent with a much duller explanation, and nobody has ruled the dull one out.
Picking up post #65: that is the part I would want checked first.
On TB-500 and thymosin beta-4 I would separate what is worth knowing from what is worth acting on. The first list is long and the second is short, and conflating them is how threads get heated.
Nothing in this subcategory is medical advice and several members here are describing experiments on themselves. Both of those things should be stated plainly rather than implied.
Happy to expand any of that if it is the useful part.
Reading rather than answering, but this is the post I would point somebody at.
Right, and stated more narrowly than I would have dared to state it.
The pentadecapeptide sequence is short and stable enough to survive conditions that would degrade a larger peptide, which is one of the few things about it that is well characterised.
Post #70 describes the usual case. This is about the unusual one.
Practical note on TB-500 and thymosin beta-4: write down what you expect before you look. The number of times I have found what I went looking for is higher than chance would allow.
Confirming post #72 from a second method, which matters more than confirming it from a second person.
I disagree with the framing of TB-500 and thymosin beta-4 above, and I think it is a substantive disagreement rather than a terminological one. Setting out why, so it can be checked.
The reasoning depends on an assumption that is doing a lot of work and is never stated. If the assumption holds, the conclusion follows. I do not think it holds generally.
Dose-response is unstudied in humans for essentially everything in this family, which means the confident numbers in circulation came from somewhere other than a trial.
That matches what I was told, which is not the same as knowing it.
The arithmetic in post #72 is right; the assumption feeding it is the part to check.
The useful distinction on TB-500 and thymosin beta-4 is between what was measured and what was inferred from it. Both end up in the same sentence and only one of them has error bars.
Adding a data point of agreement rather than a data point.
Route arguments — local versus systemic — are made confidently in this subcategory on very little published basis. The honest position is that the comparison has not been studied in humans.
The lyophilised cake is worth looking at before adding diluent. A collapsed or shrunken cake is not a purity finding but it does say something about how the vial was made and how it travelled.
This is the version I would want a new member to read first.
Post #83 answers the question as asked. The question underneath it is different.
The claim about TB-500 and thymosin beta-4 upthread is stronger than its source supports. I have read the source. The source says "associated with" and the post says "causes".
Post #83 and I disagree about the size of the effect, not about the direction.
Route arguments — local versus systemic — are made confidently in this subcategory on very little published basis. The honest position is that the comparison has not been studied in humans.
I have separated what I observed from what I concluded, which does not always happen.
The documentation on TB-500 and thymosin beta-4 is better than this thread and I say that as someone who has posted in the thread.
Nothing in this subcategory is medical advice and several members here are describing experiments on themselves. Both of those things should be stated plainly rather than implied.
I would treat the number as indicative rather than as a measurement.
The pentadecapeptide sequence is short and stable enough to survive conditions that would degrade a larger peptide, which is one of the few things about it that is well characterised.
Filing this under things that are true until someone shows me otherwise.
Building on post #87 rather than restating it.
Filing a mild objection to the consensus on TB-500 and thymosin beta-4. Mild because I might be wrong; an objection because nobody has addressed the case that does not fit.